Stepholidine

Stepholidine

SCHEMBL10001966

COc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 20/20 1.00
DRD2 P14416 15/20 1.00
DRD3 P35462 14/20 1.00
DRD5 P21918 4/20 1.00
F3 P13726 3/20 1.00
DRD4 P21917 2/20 1.00
SIGMAR1 Q99720 2/20 1.00
ADRA1D P25100 1/20 0.91
ADRA1A P35348 1/20 0.91
ADRA1B P35368 1/20 0.91
HTR1A P08908 1/20 0.89
KDM4E B2RXH2 1/20 0.78
LMNA P02545 1/20 0.78
CYP1A2 P05177 1/20 0.78
CYP3A4 P08684 1/20 0.78
CYP2D6 P10635 1/20 0.78
CASP1 P29466 1/20 0.78
CYP2C19 P33261 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Stepholidine SCHEMBL460434 1.00 DRD1 (1.00) DRD1DRD2DRD3DRD5F3
Stepholidine SCHEMBL10001965 1.00 DRD1 (1.00) DRD1DRD2DRD3DRD5F3
Stepholidine SCHEMBL29414100 1.00 DRD1 (1.00) DRD1DRD2DRD3DRD5F3
Stepholidine SCHEMBL29943869 1.00 DRD1 (1.00) DRD1DRD2DRD3DRD5F3
Corydalmine SCHEMBL21192512 0.94 DRD1 (1.00) DRD1DRD2DRD3DRD5F3
Corydalmine SCHEMBL12667453 0.94 DRD1 (1.00) DRD1DRD2DRD3DRD5F3
Corydalmine SCHEMBL29243055 0.93 DRD1 (0.98) DRD1DRD2DRD3DRD5F3
SCHEMBL14703846 0.93 DRD1 (1.00) DRD1DRD2DRD3DRD5F3
SCHEMBL680031 0.93 DRD1 (1.00) DRD1DRD2DRD3DRD5F3
SCHEMBL29561422 0.93 DRD1 (1.00) DRD1DRD2DRD3DRD5F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122018362-A HIL-based distributed drive chassis control method 厦门理工学院 2026-05-12 CN disclosed
CN-112292042-B Crystalline starch decomposition product and application thereof 昭和产业株式会社 2024-03-01 CN disclosed
EP-3517537-B1 DEUTERATED DERIVATIVE OF L-TETRAHYDROPALMATINE AND MEDICAL USE THEREOF TAIZHOU HUAYUAN MEDICINAL TECH CO LTD (CN) 2023-09-13 EP disclosed
EP-3517537-B1 DEUTERATED DERIVATIVE OF L-TETRAHYDROPALMATINE AND MEDICAL USE THEREOF TAIZHOU HUAYUAN MEDICINAL TECH CO LTD (CN) 2023-09-13 EP disclosed
US-11731965-B2 Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2023-08-22 US disclosed
US-11731965-B2 Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2023-08-22 US disclosed
CN-218974476-U Quick detection circuit of surge protector 麦王照明电器(上海)有限公司 2023-05-05 CN disclosed
WO-2023068231-A1 FOOD COMPOSITION, DRIED MATERIAL AND POWDERIZATION METHOD 株式会社ユーグレナ 2023-04-27 WO disclosed
US-20230037875-A1 SACCHARIDE FRUIT BEVERAGE HAVING IMPROVED FLAVOR AND METHOD FOR PRODUCING THE SAME KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2023-02-09 US disclosed
US-11420773-B2 Engine thrust rating architecture and processes THE BOEING COMPANY (US) 2022-08-23 US disclosed
EP-3517537-A1 DEUTERATED DERIVATIVE OF L-TETRAHYDROPALMATINE AND MEDICAL USE THEREOF Jingluweidai Information Consulting Service (Beijing) Co Ltd (CN) 2019-07-31 EP disclosed
WO-2019034031-A1 TETRAHYDROPROTOBERBERINE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF, AND PHARMACEUTICAL COMPOSITION 中国科学院上海药物研究所 2019-02-21 WO disclosed
US-20170100389-A1 TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES MILLER JAMES JACKSON (CA) 2017-04-13 US disclosed
US-9526721-B2 Tetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric and neurodegenerative diseases MILLER JAMES JACKSON (CA) 2016-12-27 US disclosed
US-20150306092-A1 TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES MILLER JAMES JACKSON (CA) 2015-10-29 US disclosed
US-8501762-B2 Tetrahydroprotoberberine compounds, the synthetic method and the use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2013-08-06 US disclosed
US-8501762-B2 Tetrahydroprotoberberine compounds, the synthetic method and the use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2013-08-06 US disclosed
WO-2012031573-A1 A METHOD FOR PREPARING AN OPTICAL ISOMERIC STEPHOLIDINE AND DERIVATES THEREOF 山东特珐曼医药原料有限公司 (CN) 2012-03-15 WO disclosed
US-20110060045-A1 ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2011-03-10 US disclosed
US-20090149488-A1 Tetrahydroprotoberberine Compounds, the Synthetic Method and the Use Thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCE (CN) 2009-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170100389-A1 TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES HTR1B, HTR2B, MAOB DRD1 124/4885DRD2 63/4885DRD3 258/4885
US-20110060045-A1 ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES INSR, GPR119, ADRB1 DRD1 1085/4885DRD2 1564/4885DRD3 784/4885
US-11731965-B2 Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition NOTUM, BHMT, CYP4F11 DRD1 448/4885DRD2 682/4885DRD3 834/4885
US-20150306092-A1 TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES HTR1B, HTR2B, MAOB DRD1 119/4885DRD2 64/4885DRD3 259/4885
US-20090149488-A1 Tetrahydroprotoberberine Compounds, the Synthetic Method and the Use Thereof CNR1, AVPR1B, MTNR1B DRD1 47/4885DRD2 20/4885DRD3 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.